GlassScriptPhysician profile
Roberta H Andrews
NPI 1659343861
$4,829.50
in general payments reported to CMS, 2019-2025
40 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $286 · 2021: $660 · 2022: $903 · 2023: $781 · 2024: $877 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.57 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $834.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $603.71 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $423.16 | 2019-2022 | |
| Pfizer INC. | $412.40 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $213.85 | 2021-2024 | |
| Abbvie INC. | $209.76 | 2021-2024 | Vraylar |
| Lilly USA, LLC | $181.75 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.56 | 2021-2023 | Trulance, Xifaxan |
| Janssen Pharmaceuticals, INC | $145.92 | 2019-2021 | |
| Mckesson Medical-Surgical, INC. | $144.59 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $141.72 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $137.75 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $132.62 | 2019-2025 | Eliquis |
| Bausch Health US, LLC | $109.33 | 2021-2024 | Aplenzin, Wellbutrin |
| Abbott Laboratories | $93.70 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.